学术周报 · IF≥10
胆胰外科领域文献阅读汇编
2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
| # | 论文 | 期刊 | IF |
|---|---|---|---|
| 1 | STING reprogramming by estrogen promotes neutrophil extracellular trap formation and sex-biased resi... | Cell | IF 45.1 |
| 2 | The use of locoregional therapies in cholangiocarcinoma. | Journal of hepatology | IF 40.1 |
| 3 | Liver transplantation for primary liver cancers in the era of transplant oncology. | Journal of hepatology | IF 40.1 |
| 4 | Advances in the imaging of liver cancer. | Journal of hepatology | IF 40.1 |
| 5 | Artificial intelligence and personalised medicine in liver cancer. | Journal of hepatology | IF 40.1 |
| 6 | Systemic therapy of biliary tract cancer: The road to personalised strategies. | Journal of hepatology | IF 40.1 |
| 7 | The changing epidemiology of primary liver cancer in the 21st century. | Journal of hepatology | IF 40.1 |
| 8 | Pushing the boundaries of liver resection for liver cancer. | Journal of hepatology | IF 40.1 |
| 9 | Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-rasG12D Inhibition in Pancre... | Gastroenterology | IF 29.7 |
| 10 | Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer. | Cancer discovery | IF 29.5 |
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Journal of hepatology | 7 | IF 40.1 |
| Gut | 3 | IF 24.6 |
| Cancer discovery | 3 | IF 29.5 |
| Cancer letters | 2 | IF 11.8 |
| Cancer research | 2 | IF 22.6 |
| Science advances | 2 | IF 13.9 |
| Cell | 1 | IF 45.1 |
| Experimental hematology & oncology | 1 | IF 17.5 |
| Endoscopy | 1 | IF 11.8 |
| Radiology | 1 | IF 17.6 |
1胰腺癌 (12篇)
临床研究 (1篇)
Individuals with diabetes are prioritised for pancreatic cancer screening. Tailored risk prediction models can improve stratification and screening efficiency. However, most existing predictive tools focus on new-onset diabetes, overlooking individuals with long-standing type 2 diabetes. To develop and validate a short-term pancreatic cancer risk prediction model applicable to both new-onset and long-standing type 2 diabetes. This retrospective longitudinal cohort study used two independent Chinese cohorts: the Tianjin Diabetes and Health Cohort (n=330 767, registration ID: NCT06913153) for derivation and internal validation, and the Xiamen Regional Electronic Health Record Database (n=105 537) for external validation. The Short-Term risk predictiOn of Pancreatic cancer in Diabetes Mellitus (STOP-DM) model was developed using a random forest algorithm and 11 routinely available clinical predictors to estimate pancreatic cancer risk at 6, 12, 24 and 36 months. Model performance was further evaluated in subgroups stratified by diabetes duration. The STOP-DM model exhibited the highest predictive performance at a 6-month time window, with the area under the receiver operating characteristic curve of 0.88 (95% CI 0.84 to 0.92) in the derivation cohort, 0.89 (0.83 to 0.94) in internal validation and 0.86 (0.83 to 0.89) in external validation. The top 5% high-risk group identified 59.37% and 48.03% of incident cases in the two validation cohorts and had 11.00-fold and 14.37-fold higher risk than the lowest-risk group. The model performed well in both new-onset and long-standing diabetes, and outperformed existing models for new-onset diabetes in sensitivity and positive predictive value. The STOP-DM model provides a practical approach to stratify pancreatic cancer risk and deliver targeted screening for individuals with type 2 diabetes, particularly those living with long-standing diabetes. Prospective validation and real-world implementation studies are warranted.
中文摘要:糖尿病患者被优先纳入胰腺癌筛查。个体化风险预测模型可改善分层和筛查效率。然而,现有预测工具大多关注新发糖尿病,忽视了长期2型糖尿病人群。本研究旨在开发并验证一个适用于新发和长期2型糖尿病的短期胰腺癌风险预测模型。这项回顾性纵向队列研究使用了两个独立的中国队列:天津市糖尿病与健康队列(n=330 767,注册号:NCT06913153)用于模型推导和内部验证,厦门区域电子健康记录数据库(n=105 537)用于外部验证。通过随机森林算法和11个常规可获得的临床预测因子构建了糖尿病中胰腺癌短期风险预测(STOP-DM)模型,用于估计6、12、24和36个月时的胰腺癌风险。并在按糖尿病病程分层的亚组中进一步评估了模型表现。STOP-DM模型在6个月时间窗预测性能最高,推导队列中受试者工作特征曲线下面积为0.88(95%CI 0.84至0.92),内部验证中为0.89(0.83至0.94),外部验证中为0.86(0.83至0.89)。前5%高危组在两个验证队列中分别识别出59.37%和48.03%的发病病例,其风险分别是最低风险组的11.00倍和14.37倍。该模型在新发和长期糖尿病中均表现良好,并在敏感度和阳性预测值方面优于针对新发糖尿病的现有模型。STOP-DM模型为2型糖尿病患者、尤其是长期2型糖尿病患者提供了一种实用的胰腺癌风险分层和针对性筛查方法。有必要开展前瞻性验证和真实世界实施研究。
基础研究 (11篇)
Liver metastasis is a common and fatal event for patients with pancreatic ductal adenocarcinoma (PDAC). Dysregulated mitochondrial dynamics reshape biological processes, including metabolism reprogramming, which disrupts immune cell function and promotes metastatic progression. To identify key drivers that reprogramme PDAC mitochondrial function and its role in remodelling the immunosuppressive tumour microenvironment (TME) during PDAC liver colonisation. Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) loss-of-function screening, in vivo mouse model screening and in vitro anoikis-resistant cell selection were employed to identify key drivers during PDAC liver colonisation. PDAC organoids, metabolic flux analysis, single-cell RNA sequencing, spatial metabolomics and glutathione S-transferase (GST) pull-down assay were used to explore the regulation of mitochondrial fission process protein 1 (MTFP1) on PDAC liver colonisation and unravel the underlying mechanism. We revealed MTFP1, a protein that plays an important role in cell viability and mitochondrial dynamics, as a driver of PDAC liver colonisation. Mechanistically, MTFP1 is recognised as a novel ATP synthase modulator through its interaction with numerous ATP synthase subunits, thereby enhancing oxidative phosphorylation (OXPHOS). Increased mitochondrial fission and subsequent redox signalling (ROS production) upregulates solute carrier family A1 member 5 (SLC1A5) expression by activating the PI3K/AKT/c-MYC pathway, competing for glutamine uptake and impaired antitumour responses of CD8+ T cells. By performing virtual screening, we identified KPT 9274 (ATG-019) as an effective inhibitor of MTFP1. Limitation of glutamine uptake in PDAC cells or MTFP1 inhibition reverses the immunosuppressive TME and reduces liver colonisation of PDAC. Our data demonstrate that the enhanced MTFP1 expression leads to an upregulated glutamine-OXPHOS axis in PDAC liver colonisation. This metabolic shift is triggered by the ROS/PI3K/AKT/c-MYC/SLC1A5 pathway. Targeting MTFP1 may be a potential therapeutic strategy for PDAC patients with liver metastasis.
中文摘要:肝转移是胰腺导管腺癌(PDAC)患者常见且致命的事件。线粒体动力学失调会重塑生物学过程,包括代谢重编程,进而破坏免疫细胞功能并促进转移进展。为鉴定重编程PDAC线粒体功能的关键驱动因素及其在PDAC肝脏定植过程中重塑免疫抑制性肿瘤微环境(TME)中的作用,采用全基因组成簇规律间隔短回文重复序列(CRISPR)功能缺失筛选、体内小鼠模型筛选和体外抗失巢凋亡细胞选择来鉴定PDAC肝脏定植过程中的关键驱动因素。利用PDAC类器官、代谢通量分析、单细胞RNA测序、空间代谢组学和谷胱甘肽S-转移酶(GST)pull-down实验,探讨线粒体分裂过程蛋白1(MTFP1)对PDAC肝脏定植的调控并揭示其潜在机制。我们发现,MTFP1是一种在细胞活力和线粒体动力学中发挥重要作用的蛋白,其为PDAC肝脏定植的驱动因素。机制上,MTFP1通过与众多ATP合酶亚基相互作用,被确认为一种新型ATP合酶调节因子,从而增强氧化磷酸化(OXPHOS)。线粒体分裂增加及随后的氧化还原信号(ROS产生)通过激活PI3K/AKT/c-MYC通路上调溶质载体家族A1成员5(SLC1A5)表达,竞争性摄取谷氨酰胺并损害CD8+ T细胞的抗肿瘤反应。通过进行虚拟筛选,我们鉴定出KPT 9274(ATG-019)是MTFP1的有效抑制剂。限制PDAC细胞中的谷氨酰胺摄取或抑制MTFP1可逆转免疫抑制性TME并减少PDAC肝脏定植。我们的数据表明,MTFP1表达增强导致PDAC肝脏定植中谷氨酰胺-OXPHOS轴上调。这种代谢转变由ROS/PI3K/AKT/c-MYC/SLC1A5通路触发。靶向MTFP1可能是伴有肝转移的PDAC患者的一种潜在治疗策略。
Over 90% pancreatic cancers harbour activating kirsten rat sarcoma viral oncogene homolog (KRAS)mutations. However, monotherapies targeting the KRAS vertical pathway, with recently developed KRAS inhibitors or rapidly accelerated fibrosarcoma (RAF)/MEK/ERK inhibitors, have demonstrated limited clinical benefit. Therefore, there is an urgent need to identify novel therapeutic targets and combination strategies with KRAS inhibition. This study aims to identify pharmaceutical targets whose inhibition suppresses pancreatic ductal adenocarcinoma (PDAC) or potentiates KRAS inhibition, focusing on molecular vulnerabilities specific to KRAS-mutant PDAC. We integrated genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 (CRISPR-associated Protein 9) dropout screens, large-scale genomic dependency datasets and pharmacological screens to identify molecular vulnerabilities in KRAS-mutant PDAC. Conditional knockout mouse models were used to assess the essentiality of candidate genes in pancreatic cancer. RNA sequencing, metabolomics/proteomics analysis and stable isotopic tracing were employed to investigate mechanisms underlying inosine monophosphate dehydrogenase 2 (IMPDH2) vulnerability. Additionally, proteolysis-targeting chimaera compounds targeting IMPDH2 were developed and evaluated in patient-derived organoid and xenograft models. Integrated screens revealed de novo guanine nucleotide biosynthesis (DNGB) as a vulnerability in KRAS-mutant PDAC, with IMPDH2 being the critical gene. Unexpectedly, IMPDH2 expression and activity are not driven by the KRAS vertical pathway. Consequently, IMPDH2 inhibition induces irreversible guanine nucleotide depletion that cannot be compensated for by mutant KRAS. Inducing guanine nucleotide depletion via targeting IMPDH2 for degradation inhibits PDAC and augments KRAS inhibitor efficacy in vitro and in vivo. These findings provide a rationale for developing combination therapies targeting KRAS and DNGB, highlighting the potential of purine nucleotide imbalance as a biomarker to guide the application of these therapies.
中文摘要:超过90%的胰腺癌携带激活性kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变。然而,靶向KRAS垂直通路的单药治疗,包括新近开发的KRAS抑制剂或快速加速纤维肉瘤(RAF)/MEK/ERK抑制剂,临床获益有限。因此,亟需确定新的治疗靶点以及与KRAS抑制联合的策略。本研究旨在确定那些被抑制后可抑制胰腺导管腺癌(PDAC)或增强KRAS抑制作用的药物靶点,重点关注KRAS突变型PDAC特有的分子脆弱性。我们整合了全基因组成簇规律间隔短回文重复序列(CRISPR)/Cas9(CRISPR相关蛋白9)敲除筛选、大规模基因组依赖性数据集和药理学筛选,以确定KRAS突变型PDAC中的分子脆弱性。使用条件性敲除小鼠模型评估候选基因在胰腺癌中的必需性。采用RNA测序、代谢组学/蛋白质组学分析和稳定同位素示踪,研究肌苷单磷酸脱氢酶2(IMPDH2)脆弱性背后的机制。此外,开发了靶向IMPDH2的蛋白水解靶向嵌合体化合物,并在患者来源的类器官和异种移植模型中进行了评估。整合筛选揭示,从头鸟嘌呤核苷酸生物合成(DNGB)是KRAS突变型PDAC的一种脆弱性,其中IMPDH2是关键基因。出乎意料的是,IMPDH2的表达和活性并非由KRAS垂直通路驱动。因此,抑制IMPDH2会诱导不可逆的鸟嘌呤核苷酸耗竭,而突变KRAS无法对此进行补偿。通过靶向IMPDH2以促使其降解来诱导鸟嘌呤核苷酸耗竭,可在体外和体内抑制PDAC并增强KRAS抑制剂的疗效。这些发现为开发靶向KRAS和DNGB的联合治疗提供了依据,并突出了嘌呤核苷酸失衡作为生物标志物以指导这些疗法应用的潜力。
Sex differences in cancer therapy response remain poorly understood. Using a "phase II-like preclinical trial" across 55 CLDN18.2+ pancreatic cancer patient-derived xenografts, we identify marked female-biased resistance to CLDN18.2-targeted antibody-drug conjugate (ADC) therapy despite equivalent antigen expression. Mechanistically, estrogen signals through GPER1 to upregulate TRAF6, redirecting tumor-intrinsic STING signaling from IRF3-mediated interferon production toward nuclear factor κB (NF-κB) activation. This drives CXCL1 secretion, neutrophil recruitment, and neutrophil extracellular trap (NET) formation. NETs form a charged extracellular network that restricts antibody access to tumor-cell-surface antigens-a mechanism we term functional antigen shielding-reducing ADC cytotoxicity independently of antigen expression. The NET burden also correlated with poorer responses to trastuzumab, cetuximab, and enfortumab vedotin across three clinical cohorts. Pharmacologic NET disruption with sivelestat restored ADC efficacy in female mice. These findings reveal an estrogen-driven resistance mechanism with broad implications for antibody-based cancer therapy.
中文摘要:癌症治疗反应中的性别差异仍知之甚少。我们利用一项覆盖55例CLDN18.2阳性胰腺癌患者来源异种移植瘤的「II期样临床前试验」,发现尽管抗原表达相当,女性仍对CLDN18.2靶向抗体-药物偶联物(ADC)治疗表现出明显的耐药倾向。机制上,雌激素通过GPER1信号上调TRAF6,使肿瘤内在的STING信号从IRF3介导的干扰素产生转向核因子κB(NF-κB)激活。这驱动CXCL1分泌、中性粒细胞募集和中性粒细胞胞外诱捕网(NET)形成。NET形成带电荷的细胞外网络,限制抗体接近肿瘤细胞表面抗原——我们将这一机制称为功能性抗原屏蔽——从而在不依赖抗原表达的情况下降低ADC的细胞毒性。NET负荷也与三个临床队列中对曲妥珠单抗、西妥昔单抗和恩诺单抗维多汀较差的反应相关。使用西维来司他进行药理学NET破坏可恢复雌性小鼠中的ADC疗效。这些发现揭示了一种雌激素驱动的耐药机制,对抗体为基础的癌症治疗具有广泛意义。
Aberrant epigenetic regulation is a central driver of tumorigenesis, and the reversibility of epigenetic modifications underscores their potential as therapeutic targets. Epigenetic factors often function in a highly context-dependent manner, necessitating rigorous study of their dynamic and complex roles. Here, we uncovered an intricate regulation of tumor development and plasticity by the KDM6 family of H3K27me3 histone demethylases in pancreatic ductal adenocarcinoma (PDAC), a disease with sustained high mortality and limited treatment options. Temporally resolving KRAS-driven tumor development revealed a switch from tumor suppressive to oncogenic functions for KDM6B, with implications for tumor aggressiveness in rodents and patients. These oncogenic functions were mediated by regulation of NOTCH signaling, a pathway known to promote PDAC tumorigenesis. Concurrent elimination of KDM6A and KDM6B led to profound phenotypic changes resembling sarcomatoid carcinomas, a rare, poorly characterized subtype of human PDAC. These tumors exhibited altered oncogenic networks, including NOTCH and JNK signaling, that may support development of therapies tailored to molecular subtypes. Given the critical and distinct activities of KDM6 histone demethylases during PDAC development, targeting KDM6 activities may be beneficial in the right cellular and temporal context.
中文摘要:异常的表观遗传调控是肿瘤发生的核心驱动因素,而表观遗传修饰的可逆性凸显了其作为治疗靶点的潜力。表观遗传因子常以高度依赖背景的方式发挥作用,因此需要对其动态且复杂的作用进行严格研究。在此,我们揭示了KDM6家族H3K27me3组蛋白去甲基化酶在胰腺导管腺癌(PDAC)中对肿瘤发展和可塑性的复杂调控;PDAC是一种死亡率持续较高且治疗选择有限的疾病。对KRAS驱动的肿瘤发展进行时间分辨分析显示,KDM6B从抑癌功能向致癌功能发生转换,这对啮齿动物和患者的肿瘤侵袭性具有意义。这些致癌功能由对NOTCH信号的调控所介导,而NOTCH信号是已知可促进PDAC肿瘤发生的通路。同时消除KDM6A和KDM6B会导致类似肉瘤样癌的显著表型改变,肉瘤样癌是人类PDAC中一种罕见且特征不明的亚型。这些肿瘤表现出改变的致癌网络,包括NOTCH和JNK信号,这可能支持开发针对分子亚型定制的疗法。鉴于KDM6组蛋白去甲基化酶在PDAC发展过程中具有关键且不同的活性,在正确的细胞和时间背景下靶向KDM6活性可能有益。
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic cancers but has shown limited efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC). The cellular and molecular factors that influence CAR T cell therapy response remain largely unknown. By integrating modular in vivo CRISPR screens with single-cell genomics and immunocompetent orthotopic models of PDAC, we uncover oxidative and proteotoxic stress pathways as previously unknown modulators of CAR T cell therapy response. Disruption of stress regulatory genes, particularly Keap1 and Slc33a1, sensitizes PDAC tumors to CAR T cell killing in vivo. Hyperactivation of the Nrf2 pathway by genetic ablation of Keap1 or endogenous engineering of clinically observed Keap1 or Nfe2l2 mutations enhances tumor susceptibility to CAR T cell therapy. Thus, tumor-intrinsic molecular stress phenotypes can induce unexpected cell state-specific vulnerabilities to cell-based immunotherapies. These findings provide a foundation to improve efficacy of CAR T cell therapy in solid malignancies and to better stratify patients with cancer by tumor genotype.
中文摘要:嵌合抗原受体(CAR)T细胞疗法已改变血液系统恶性肿瘤的治疗,但在包括胰腺导管腺癌(PDAC)在内的实体瘤中疗效有限。影响CAR T细胞疗法反应的细胞和分子因素在很大程度上仍然未知。通过将模块化体内CRISPR筛选与单细胞基因组学及免疫健全的PDAC原位模型相整合,我们发现氧化应激和蛋白质毒性应激通路是此前未知的CAR T细胞疗法反应调节因子。破坏应激调控基因,尤其是Keap1和Slc33a1,可使PDAC肿瘤在体内对CAR T细胞杀伤敏感。通过基因敲除Keap1或对临床观察到的Keap1或Nfe2l2突变进行内源性工程化来过度激活Nrf2通路,可增强肿瘤对CAR T细胞疗法的易感性。因此,肿瘤内在的分子应激表型可诱导对细胞免疫疗法产生出乎意料的细胞状态特异性脆弱性。这些发现为改善CAR T细胞疗法在实体恶性肿瘤中的疗效,并根据肿瘤基因型更好地对癌症患者进行分层提供了基础。
Maintenance of fissed mitochondria is viewed as a defining feature of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers. However, regulation of this process by accompanying comutations or environmental factors is not clearly defined. Here, by analyzing a subset of pancreatic cancer lesions driven by concurrent KrasG12D and GNAS complex locus gene (GNASR201C/H) mutations, we found that despite the presence of mutant Kras, hyperactive GnasR201C maintains mitochondria predominantly in a fused state, which is necessary for tumor growth. Multiplex proteomics, super-resolution microscopy, loss- and gain-of-function studies, coupled with metabolite rescue experiments, revealed that GnasR201C-regulated branched-chain amino acid (BCAA) pathway is a previously unidentified regulator of mitochondrial morphology. Mechanistically, the BCAA pathway, the associated tricarboxylic acid cycle, and aspartate metabolism converge on nicotinamide adenine dinucleotide (NADH-NAD+) metabolites to promote mitochondrial elongation. NAD+ availability is crucial for mitochondrial fusion, as facilitating NAD+ generation through alternative means promotes fusion. Collectively, we unraveled a new mechanism that drives mitochondrial fusion and showed that the combination of oncogenic signaling and metabolism can maintain distinct mitochondrial morphology within genetic subsets of KRAS-mutant pancreatic cancer.
中文摘要:维持断裂的线粒体被视为Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变癌症的一个决定性特征。然而,伴随共突变或环境因素对这一过程的调控尚不明确。在此,通过分析由KrasG12D与GNAS复杂位点基因(GNASR201C/H)突变共同驱动的一部分胰腺癌病变,我们发现尽管存在突变Kras,过度活跃的GnasR201C仍使线粒体主要维持融合状态,而这对肿瘤生长是必需的。多重蛋白质组学、超分辨率显微镜、功能缺失和功能获得研究,结合代谢物挽救实验,揭示GnasR201C调控的支链氨基酸(BCAA)途径是线粒体形态的一个此前未被识别的调控因子。在机制上,BCAA途径、相关的三羧酸循环以及天冬氨酸代谢汇聚于烟酰胺腺嘌呤二核苷酸(NADH-NAD+)代谢物,以促进线粒体延长。NAD+的可利用性对线粒体融合至关重要,因为通过替代方式促进NAD+生成可促进融合。总之,我们揭示了一种驱动线粒体融合的新机制,并表明致癌信号与代谢的结合可在KRAS突变胰腺癌的遗传亚群中维持不同的线粒体形态。
Cancer-associated fibroblasts (CAF) are principal determinants of pancreatic ductal adenocarcinoma (PDAC) progression. CAFs can shape tumor behavior via multiple pathways, underscoring the need for a complete understanding of the regulatory mechanisms that govern CAF function. In this study, we identified N6-methyladenosine (m6A) remodeling as a hallmark of CAF activation and defined a critical role for the m6A demethylase ALKBH5 in PDAC metastasis. Activated CAFs exhibited a global reduction in m6A abundance, with ALKBH5 emerging as a key regulator of the CAF epitranscriptome. Functionally, CAF-derived ALKBH5 enhanced pancreatic cancer cell migration and invasion in vitro and promoted epithelial-mesenchymal transition-associated gene expression in tumor cells in an m6A-dependent manner. Orthotopic co-implantation models and host genetic ablation models demonstrated that ALKBH5 plays a critical role in metastatic dissemination, with minimal impact on primary tumor growth. Mechanistically, ALKBH5 enhanced the m6A-dependent translation of HSF1 in CAFs, at least in part by relieving insulin-like growth factor 2 mRNA-binding protein 3-associated translational constraints. Elevated HSF1 subsequently activated leukemia-inhibitory factor (LIF) transcription through distal enhancer elements, establishing an ALKBH5-HSF1-LIF signaling axis that mediated the prometastatic CAF-tumor cell communication. Clinically, enrichment of ALKBH5+HSF1+ CAFs independently predicted poor prognosis and was preferentially observed in metastatic PDAC. Collectively, these findings uncover a CAF-intrinsic epitranscriptomic program that drives PDAC metastasis and highlight stromal m6A regulation as a potential therapeutic vulnerability. Cancer-associated fibroblast-intrinsic ALKBH5 facilitates metastatic dissemination in pancreatic ductal adenocarcinoma via m6A-dependent HSF1-LIF paracrine signaling, uncovering a stroma-specific vulnerability with therapeutic relevance in pancreatic cancer.
中文摘要:癌症相关成纤维细胞(CAF)是胰腺导管腺癌(PDAC)进展的主要决定因素。CAF可通过多种途径塑造肿瘤行为,这凸显出全面理解调控CAF功能的机制的必要性。在本研究中,我们发现N6-甲基腺苷(m6A)重塑是CAF激活的一个标志,并明确了m6A去甲基化酶ALKBH5在PDAC转移中的关键作用。活化的CAF表现出m6A丰度的整体降低,而ALKBH5成为CAF表观转录组的关键调控因子。在功能上,CAF来源的ALKBH5在体外增强胰腺癌细胞迁移和侵袭,并以m6A依赖的方式促进肿瘤细胞中上皮-间质转化相关基因表达。原位共植入模型和宿主基因敲除模型表明,ALKBH5在转移播散中发挥关键作用,而对原发肿瘤生长影响甚微。在机制上,ALKBH5增强CAF中HSF1的m6A依赖性翻译,至少部分是通过解除胰岛素样生长因子2 mRNA结合蛋白3相关的翻译限制实现的。升高的HSF1随后通过远端增强子元件激活白血病抑制因子(LIF)转录,建立ALKBH5-HSF1-LIF信号轴,该信号轴介导促转移性CAF-肿瘤细胞通讯。在临床上,ALKBH5+HSF1+ CAF的富集可独立预测不良预后,并且优先见于转移性PDAC。总之,这些发现揭示了一个驱动PDAC转移的CAF内在表观转录组程序,并强调基质m6A调控是一个潜在的治疗脆弱点。CAF内在的ALKBH5通过m6A依赖性HSF1-LIF旁分泌信号促进胰腺导管腺癌的转移播散,揭示了一个在胰腺癌中具有治疗相关性的基质特异性脆弱点。
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly aggressive phenotype and limited therapeutic options, primarily attributable to diagnostic delays and intrinsic chemotherapy resistance, thereby underscoring the critical need for the development of more effective therapeutic strategies. Tripterine (TP) is a natural compound with potent antitumor activity, but has shown limited clinical use due to its multi-organ toxicity. Here, we overcame this limitation by formulating TP into liposomes (TP-lipo). We evaluated the therapeutic potential of TP-lipo showing that TP-lipo exhibited antitumor activity in vitro (murine Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+ pancreatic cancer cells, KPC cells) and in vivo (PDAC mouse) models. TP-lipo reshaped the tumor immune microenvironment by promoting macrophage polarization toward the M1 phenotype, increasing the proportion of interferon-γ (IFN-γ)-secreting CD8+ T cells. In vitro, TP-lipo promoted IFN-γ and granzyme B production in CD8+ T cells, while TP-lipo-pretreated macrophages enhanced T-cell differentiation into cytotoxic T lymphocytes. Notably, combination therapy with TP-lipo and PD-1 antagonist exerted a synergistic antitumor effect and significantly prolonged median survival in PDAC-bearing mice. TP-lipo showed substantially lower toxicity than the free drug, highlighting its improved safety profile and therapeutic potential. Collectively, these findings suggest TP-lipo, particularly in combination with PD-1 blockade, as a promising therapeutic strategy for PDAC.
中文摘要:胰腺导管腺癌(PDAC)具有高度侵袭性表型和有限治疗选择,主要归因于诊断延迟和内在化疗耐药,因此亟需开发更有效的治疗策略。雷公藤红素(TP)是一种具有强效抗肿瘤活性的天然化合物,但由于其多器官毒性,临床使用受限。在此,我们通过将TP制成脂质体(TP-lipo)克服了这一限制。我们评估了TP-lipo的治疗潜力,显示TP-lipo在体外(小鼠Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+胰腺癌细胞,即KPC细胞)和体内(PDAC小鼠)模型中均具有抗肿瘤活性。TP-lipo通过促进巨噬细胞向M1表型极化、增加分泌干扰素-γ(IFN-γ)的CD8+ T细胞比例,重塑了肿瘤免疫微环境。在体外,TP-lipo促进CD8+ T细胞产生IFN-γ和颗粒酶B,而经TP-lipo预处理的巨噬细胞增强T细胞向细胞毒性T淋巴细胞分化。值得注意的是,TP-lipo与PD-1拮抗剂联合治疗发挥了协同抗肿瘤作用,并显著延长了荷PDAC小鼠的中位生存期。TP-lipo显示出较游离药物显著更低的毒性,突出其改善的安全性特征和治疗潜力。总之,这些发现表明TP-lipo,尤其是与PD-1阻断联合,是PDAC的一种有前景的治疗策略。
Oncogenic de novo mucins (oncoMUCs; MUC4, MUC16, and MUC5AC) are progressively upregulated in pancreatic ductal adenocarcinoma (PDA). Although their individual cell-intrinsic roles have been investigated, their collective impact on PDA progression and the tumor microenvironment (TME) remains unclear. Evaluating the patient-centric impact of oncoMUCs on the TME will inform diagnostic and therapeutic strategies. Integration of single-cell RNA sequencing (n = 34), multiplex/sequential immunostaining, and murine models characterized the oncomucinome. Immune suppression was investigated using NanoString profiling and gene silencing. Pharmacologic oncoMUC targeting (Istradefylline) was evaluated in combination with K-rasG12D inhibitor in a syngeneic murine model. OncoMUCs showed extensive clonal diversity and survival disadvantage (P = .00013) in PDA. OncoMUC4 and oncoMUC16 subpopulations were enriched after stage IIA/B, and their deletion significantly reduced immune checkpoints (ICs) expression (V-domain immunoglobulin suppressor of T-cell activation [VISTA]: P < .0001, .001; T-cell immunoglobulin and mucin domain-containing protein 3 [TIM3]: P < .0001, .001), and increased CD8+ T-cell (P = .0087) and antigen-presenting cell infiltration (macrophages: P < .004; dendritic cells: P = .021) in tumors of PDA autochthonous models. Mechanistically, these subpopulations potentiate epidermal growth factor receptor (EGFR) and Unc-5 Netrin Receptor B (UNC5B) signaling, which collaboratively upregulate ICs, VISTA, and programmed death ligand 1 ([PD-L1] P < .0001). As KrasG12D inhibition (MRTX1133) upregulated oncoMuc4 and oncoMuc16 expression, pharmacological targeting of oncoMUCs enhanced the efficacy of MRTX1133, as indicated by reduced tumor burden (P = .034), ICs (local, [P range 0.03-0.009] and systemic VISTA and TIM3 [P = .024, .014]), and Unc5b (P = .048) expression. Transmembrane oncoMUCs promote immune evasion in PDA through EGFR/UNC5B signaling, and their targeting enhances the efficacy of K-rasG12D inhibition, suggesting oncoMUCs as novel immune regulators and therapeutic targets in PDA.
中文摘要:致癌性从头合成黏蛋白(oncoMUCs;MUC4、MUC16和MUC5AC)在胰腺导管腺癌(PDA)中逐渐上调。尽管其各自的细胞内在作用已有研究,但它们对PDA进展和肿瘤微环境(TME)的总体影响仍不清楚。评估oncoMUCs对TME以患者为中心的影响将为诊断和治疗策略提供信息。整合单细胞RNA测序(n=34)、多重/序贯免疫染色和小鼠模型,表征了肿瘤黏蛋白组。使用NanoString谱分析和基因沉默研究免疫抑制。在同基因小鼠模型中评估了药理学oncoMUC靶向(Istradefylline)与K-rasG12D抑制剂的联合应用。oncoMUCs在PDA中显示出广泛的克隆多样性和生存劣势(P=0.00013)。oncoMUC4和oncoMUC16亚群在IIA/B期后富集,它们的缺失显著降低了免疫检查点(ICs)表达(V域免疫球蛋白T细胞活化抑制因子[VISTA]:P<0.0001、0.001;含T细胞免疫球蛋白和黏蛋白结构域蛋白3[TIM3]:P<0.0001、0.001),并增加了PDA自发模型肿瘤中CD8+ T细胞(P=0.0087)和抗原提呈细胞浸润(巨噬细胞:P<0.004;树突状细胞:P=0.021)。在机制上,这些亚群增强表皮生长因子受体(EGFR)和Unc-5 Netrin受体B(UNC5B)信号,后者协同上调ICs、VISTA和程序性死亡配体1(PD-L1,P<0.0001)。由于KrasG12D抑制(MRTX1133)上调了oncoMuc4和oncoMuc16表达,药理学靶向oncoMUCs增强了MRTX1133的疗效,表现为肿瘤负荷减少(P=0.034)、ICs(局部,P范围0.03-0.009;全身VISTA和TIM3,P=0.024、0.014)以及Unc5b(P=0.048)表达降低。跨膜oncoMUCs通过EGFR/UNC5B信号促进PDA中的免疫逃逸,靶向它们可增强K-rasG12D抑制的疗效,提示oncoMUCs是PDA中新型免疫调节因子和治疗靶点。
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive cancer development remains unresolved. Leveraging an oncogenic Kras-driven mouse model that closely mimics human PDAC progression, we screened a dozen isocaloric HFDs differing solely in fat source and representing the diversity of human fat consumption. Unexpectedly, diets rich in oleic acid-a monounsaturated fatty acid (MUFA) typically associated with good health-markedly enhanced tumorigenesis. Conversely, diets high in polyunsaturated fatty acids (PUFA) suppressed tumor progression. Relative dietary fatty acid saturation levels (PUFA/MUFA) governed pancreatic membrane phospholipid composition, lipid peroxidation, and ferroptosis sensitivity in mice, concordant with circulating PUFA/MUFA levels being linked to altered PDAC risk in humans. These findings directly implicate dietary unsaturated fatty acids in controlling ferroptosis susceptibility and tumorigenesis, supporting potential "precision nutrition" strategies for PDAC prevention. This study reveals that dietary unsaturated fatty acids divergently influence pancreatic cancer progression by incorporating into tissue phospholipids to modulate ferroptosis sensitivity. Dietary MUFAs promote tumorigenesis, whereas PUFAs confer protection. These findings suggest that alterations in dietary fat intake could affect cancer risk. See related commentary by Jeong and Lien, p. 1961.
中文摘要:高脂饮食(HFD)摄入与胰腺导管腺癌(PDAC)风险增加相关,而PDAC是一种致死性强且治疗抵抗的癌症。然而,特定膳食脂肪是否以及如何驱动癌症发生仍未明确。利用一种由致癌性Kras驱动、可密切模拟人类PDAC进展的小鼠模型,我们筛选了十余种等热量HFD,它们仅脂肪来源不同,并代表了人类脂肪摄入的多样性。出乎意料的是,富含油酸的饮食——一种通常被认为有益健康的单不饱和脂肪酸(MUFA)——显著增强了肿瘤发生。相反,富含多不饱和脂肪酸(PUFA)的饮食抑制了肿瘤进展。膳食脂肪酸相对饱和度(PUFA/MUFA)决定了小鼠胰腺膜磷脂组成、脂质过氧化和铁死亡敏感性,这与人类循环PUFA/MUFA水平与PDAC风险改变相关相一致。这些发现直接提示膳食不饱和脂肪酸控制铁死亡易感性和肿瘤发生,支持用于PDAC预防的潜在「精准营养」策略。本研究揭示,膳食不饱和脂肪酸通过掺入组织磷脂以调节铁死亡敏感性,从而对胰腺癌进展产生不同影响。膳食MUFA促进肿瘤发生,而PUFA提供保护。这些发现提示,膳食脂肪摄入的改变可能影响癌症风险。参见Jeong和Lien的相关评论,第1961页。
Fluorescent molecular probes are promising imaging tools for tumor surgical navigation. However, achieving both precise diagnosis and long-term surgical navigation in complex tumor environments remains challenging. In this study, we developed a "catch and light-up" fluorescent probe (CyTB) that enables specific fluorescence retention and activation, thereby enhancing imaging navigation accuracy. The probe consists of a hemicyanine unit as the near-infrared fluorescence signal reporter, tetrazine (Tz) reactive group bicyclo [6.1.0]nonyne (BCN) and trans-cyclooctene (TCO). Once arrival at the tumor site labeled by Tz in advance, the BCN group of probes was anchored through ligation reaction to enhance the probe retention. Concurrently, the TCO group can rapidly be cleaved by Tz leading to the light-up of fluorescence. The retention time of the probe at the tumor site can reach 130 h, while the tumor-to-normal tissue ratio in metastatic microtumor of pancreatic cancer (< 2 mm) still reaches 6.5, enabling efficient tumor tracking and precise marginal resection, thus providing a promising strategy for surgical navigation.
中文摘要:荧光分子探针是用于肿瘤手术导航的有前景的成像工具。然而,在复杂肿瘤环境中同时实现精准诊断和长期手术导航仍具挑战性。在本研究中,我们开发了一种「捕获并点亮」荧光探针(CyTB),其能够实现特异性荧光滞留和激活,从而提高成像导航准确性。该探针由作为近红外荧光信号报告基团的半花菁单元、四嗪(Tz)反应基团、双环[6.1.0]壬炔(BCN)和反式环辛烯(TCO)组成。当探针到达预先用Tz标记的肿瘤部位后,探针的BCN基团通过连接反应被锚定,以增强探针滞留。同时,TCO基团可被Tz快速裂解,导致荧光点亮。探针在肿瘤部位的滞留时间可达130 h,而在胰腺癌转移性微肿瘤(< 2 mm)中,肿瘤与正常组织的比值仍达到6.5,从而能够实现高效的肿瘤追踪和精准的边缘切除,为手术导航提供了一种有前景的策略。
2胆管癌/胆道手术 (5篇)
临床研究 (3篇)
Evidence regarding the survival benefit of endobiliary radiofrequency ablation (RFA) in perihilar cholangiocarcinoma (CCA) remains limited. We evaluated the association between endobiliary RFA and overall survival in unresectable perihilar CCA, with a focus on the timing of exposure. This retrospective cohort study included 475 patients with unresectable perihilar CCA treated with endoscopic biliary drainage between 2015 and 2025 (90 with a single RFA session, 50 with two or more). RFA was modeled as a time-dependent cumulative count (0, 1, or ≥2 sessions), with landmark analyses of subsequent 6-month mortality at baseline and 3, 6, 9, and 12 months. Sensitivity analyses adjusted for stent type and calendar year. RFA within 7 days of drainage was associated with lower 6-month mortality (adjusted hazard ratio [aHR], 0.34; 95% CI, 0.16-0.70; P=0.004). At the 3-month landmark, two or more sessions were associated with lower mortality (aHR, 0.10; P=0.024); no association was seen at later landmarks. These estimates were unchanged after adjustment for stent type and calendar year. Over the entire follow-up, two or more sessions were associated with lower mortality (aHR, 0.59; P=0.007), but this association was attenuated after adjustment for calendar year (aHR, 0.77; P=0.209). Recurrent biliary obstruction was more frequent after RFA (37.9% vs. 22.1%; P<0.001), with the excess confined to non-tumor causes. Endobiliary RFA was associated with improved survival in unresectable perihilar CCA, with the benefit concentrated in the first three months after biliary drainage, at the cost of more frequent non-tumor biliary obstruction.
中文摘要:关于胆管内射频消融(RFA)对肝门部胆管癌(CCA)生存获益的证据仍有限。我们评估了胆管内RFA与不可切除肝门部CCA总生存之间的关联,并重点关注暴露时机。这项回顾性队列研究纳入2015年至2025年间接受内镜下胆道引流治疗的475例不可切除肝门部CCA患者(90例接受单次RFA,50例接受两次或以上)。将RFA建模为时间依赖性累积次数(0次、1次或≥2次),并在基线以及3、6、9和12个月时对随后6个月死亡率进行界标分析。敏感性分析针对支架类型和日历年进行调整。引流后7天内行RFA与较低的6个月死亡率相关(调整后风险比[aHR]为0.34;95% CI 0.16-0.70;P=0.004)。在3个月界标分析中,两次或以上RFA与较低死亡率相关(aHR为0.10;P=0.024);在更晚的界标分析中未观察到这种关联。在针对支架类型和日历年进行调整后,这些估计值未发生变化。在整个随访期间,两次或以上RFA与较低死亡率相关(aHR为0.59;P=0.007),但在针对日历年进行调整后,这种关联减弱(aHR为0.77;P=0.209)。RFA后复发性胆道梗阻更常见(37.9% vs. 22.1%;P<0.001),且超出的部分仅限于非肿瘤性原因。胆管内RFA与不可切除肝门部CCA生存改善相关,获益主要集中在胆道引流后的前三个月,代价是更频繁的非肿瘤性胆道梗阻。
The standard of care for patients with unresectable or advanced cholangiocarcinoma (CCA) is systemic chemotherapy combined with immunotherapy, which achieves a median overall survival (OS) of 13 months and a 3-year OS of 15%. This provides the benchmark against which additional locoregional therapies are evaluated. This narrative literature review examined locoregional therapies, their clinical outcomes, and recommendations for their role in the management of patients with CCA. The review focused on intrahepatic (iCCA) and perihilar CCA (pCCA) with locoregional disease in patients who were ineligible for surgical resection. A literature search was conducted in PubMed (MEDLINE) to identify clinical studies evaluating locoregional therapies in CCA. Ongoing and completed trials were identified through ClinicalTrials.gov. For iCCA, clinical trials have evaluated percutaneous image-guided local ablative therapies, including radiofrequency ablation or microwave ablation (3-year OS 42%), cryoablation, interstitial electroporation, and brachytherapy. Other trials have analysed external beam radiotherapy (EBRT), often using high-precision techniques (3-year OS 38%), as well as intra-arterial therapies, including transarterial chemoembolisation (3-year OS 17%), selective internal radioembolisation (3-year OS 40%), and floxuridine delivery through a hepatic arterial infusion pump (3-year OS 26-50%). For pCCA, EBRT has been evaluated in three treatment settings: definitive therapy (1-year OS 100%), adjuvant postoperative therapy (3-year OS 58%), and neoadjuvant therapy before liver transplantation (3-year OS 62%). Recent and ongoing clinical trials demonstrate a clear trend toward combining locoregional and standard-of-care systemic therapies. Few randomised controlled trials have been conducted. Until further evidence from randomised controlled trials becomes available, treatment strategies for patients with unresectable or advanced CCA should be individualised, incorporating flexible, staged combinations of locoregional and systemic therapies within a personalised therapeutic framework. These decisions should be made within a multidisciplinary tumour board.
中文摘要:不可切除或晚期胆管癌(CCA)患者的标准治疗是全身化疗联合免疫治疗,其中位总生存期(OS)为13个月,3年OS为15%。这为评估其他局部区域治疗提供了基准。本叙述性文献综述考察了局部区域治疗、其临床结局及其在CCA患者管理中的作用建议。综述聚焦于不适合手术切除、存在局部区域病变的肝内胆管癌(iCCA)和肝门部胆管癌(pCCA)。在PubMed(MEDLINE)中进行文献检索,以识别评估CCA局部区域治疗的临床研究。通过ClinicalTrials.gov识别正在进行和已完成的试验。对于iCCA,临床试验评估了经皮影像引导局部消融治疗,包括射频消融或微波消融(3年OS 42%)、冷冻消融、间质电穿孔和近距离放疗。其他试验分析了外照射放疗(EBRT),常采用高精度技术(3年OS 38%),以及动脉内治疗,包括经动脉化疗栓塞(3年OS 17%)、选择性内放射治疗(3年OS 40%)和通过肝动脉灌注泵给予氟尿苷(3年OS 26-50%)。对于pCCA,EBRT已在三种治疗情境中接受评估:根治性治疗(1年OS 100%)、术后辅助治疗(3年OS 58%)和肝移植前新辅助治疗(3年OS 62%)。近期和正在进行的临床试验显示出将局部区域治疗与标准全身治疗联合的明显趋势。已开展的随机对照试验很少。在获得随机对照试验的进一步证据之前,不可切除或晚期CCA患者的治疗策略应个体化,在个体化治疗框架内纳入灵活、分阶段的局部区域治疗和全身治疗组合。这些决策应在多学科肿瘤委员会内做出。
Biliary tract cancers (BTC), including cholangiocarcinoma, gallbladder cancer, and ampullary cancer, remain poor-prognosis tumours. Chemo-immunotherapy is now established as the first-line standard of care. In parallel, precision medicine is now well established in the form of targeted therapies. These have transformed outcomes for defined subgroups, particularly intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements, where pemigatinib and futibatinib provide meaningful response rates and durable disease control. On top of this, next-generation FGFR inhibitors aim to address secondary resistance. IDH1-mutant cholangiocarcinoma benefits from ivosidenib, with multiple combination strategies currently under investigation. HER2-directed therapies, including zanidatamab and trastuzumab deruxtecan, have shown promising efficacy in HER2-amplified or strongly overexpressing BTC, with ongoing clinical trials in the first-line setting. Tumour-agnostic targets (BRAF V600E, MSI-H/dMMR, RET/NTRK/NRG1 fusions) and other emerging therapies are further broadening therapeutic opportunities. However, key barriers to implementation include heterogeneous biomarker testing, limited tissue availability, the need for DNA/RNA hybrid-capture sequencing, and evolving resistance biology, underscoring the importance of optimised diagnostics and innovative trial designs to realise personalised care in BTC. This review provides detailed insights on these therapies, and most importantly a view to what the future may hold.
中文摘要:胆道癌(BTC),包括胆管癌、胆囊癌和壶腹癌,仍是预后不良的肿瘤。化疗联合免疫治疗现已成为一线标准治疗。与此同时,精准医学现已通过靶向治疗的形式牢固确立。这些治疗已改变了特定亚组的结局,尤其是伴有FGFR2融合/重排的肝内胆管癌,佩米替尼和福巴替尼在其中提供了有意义的缓解率和持久的疾病控制。在此基础上,下一代FGFR抑制剂旨在解决继发性耐药。IDH1突变胆管癌可从艾伏尼布获益,目前有多种联合策略正在研究中。HER2导向治疗,包括赞尼达单抗和德曲妥珠单抗,在HER2扩增或强过表达的BTC中显示出有前景的疗效,一线治疗中的临床试验正在进行。肿瘤不可知靶点(BRAF V600E、MSI-H/dMMR、RET/NTRK/NRG1融合)及其他新兴疗法正在进一步拓宽治疗机会。然而,实施的关键障碍包括生物标志物检测异质性、组织可用性有限、需要DNA/RNA混合捕获测序以及不断演变的耐药生物学,这凸显了优化诊断和创新试验设计以实现BTC个体化治疗的重要性。本综述对这些治疗提供了详细见解,最重要的是展望了未来可能的方向。
基础研究 (2篇)
Lymph node metastasis (LNM) is a major determinant of staging and outcome in cholangiocarcinoma (CCA), yet its mechanisms, biomarkers, anatomical heterogeneity, and treatment evidence remain insufficiently integrated. This review develops an LNM-centered framework in which lymphatic invasion, lymphangiogenesis, genomic alterations and metabolic reprogramming, and reciprocal tumor microenvironment remodeling interact to shape CCA LNM by enabling lymphatic entry, dissemination, immune evasion, tumor-cell survival, and nodal colonization. A subtype-aware synthesis distinguishes small-duct-type and large-duct-type intrahepatic CCA, positions the latter as a biological bridge to perihilar and distal CCA, and maps subtype-associated lymphangiogenic, matrix-remodeling, metabolic, stromal, and immune programs. Translationally, serum ANGPTL4 and exosomal TTN-AS1 are prioritized as candidate adjuncts to preoperative radiologic nodal assessment and CA19-9, whereas tissue ITGB6 represents a comparatively well-characterized candidate for postoperative or biopsy-integrated LNM risk assessment. For node-positive CCA requiring systemic therapy, PD-1/PD-L1 blockade plus gemcitabine-cisplatin provides the first-line backbone. Additional opportunities include intensified chemoimmunotherapy and antiangiogenic combinations, postoperative and locoregional multimodal treatment, genotype-directed or cellular therapies, and mechanism-informed targeting of chemoresistance, oncogenic and lymphangiogenic signaling, stromal and immune niches, and metabolic adaptation. Epigenetic circuitry and post-transcriptional regulation represent emerging regulatory layers, while microbiome-immune interactions provide testable hypotheses for LNM. We propose spatial multi-omics across paired primary tumors, pathologically negative tumor-draining nodes, and metastatic nodes, integrated with pathology-validated liquid biopsy, to identify where metastatic competence emerges and how nodal niches are conditioned. Together, this mechanism-to-clinic synthesis provides a subtype-aware roadmap for biomarker validation, LNM-specific endpoints, and rational therapeutic intervention.
中文摘要:淋巴结转移(LNM)是胆管癌(CCA)分期和结局的主要决定因素,然而其机制、生物标志物、解剖异质性及治疗证据仍未得到充分整合。本综述构建了一个以LNM为中心的框架,其中淋巴管侵犯、淋巴管生成、基因组改变与代谢重编程以及相互的肿瘤微环境重塑相互作用,通过促使淋巴管进入、播散、免疫逃逸、肿瘤细胞存活和淋巴结定植来塑造CCA LNM。基于亚型的综合分析区分小胆管型和大胆管型肝内CCA,将后者定位为通向肝门部和远端CCA的生物学桥梁,并绘制了与亚型相关的淋巴管生成、基质重塑、代谢、间质和免疫程序。在转化方面,血清ANGPTL4和外泌体TTN-AS1被优先作为术前影像学淋巴结评估和CA19-9的候选辅助指标,而组织ITGB6则是相对更充分表征的、用于术后或活检整合的LNM风险评估候选标志物。对于需要系统性治疗的淋巴结阳性CCA,PD-1/PD-L1阻断联合吉西他滨-顺铂提供了一线骨架。其他机会包括强化化疗免疫治疗和抗血管生成联合治疗、术后和局部区域多模式治疗、基因型导向或细胞治疗,以及基于机制的化疗耐药、致癌和淋巴管生成信号、基质和免疫生态位及代谢适应的靶向治疗。表观遗传回路和转录后调控代表新兴的调控层面,而微生物组-免疫相互作用为LNM提供了可检验的假设。我们提出对配对的原发肿瘤、病理阴性肿瘤引流淋巴结和转移淋巴结开展空间多组学,并与经病理验证的液体活检相结合,以识别转移能力在何处出现以及淋巴结生态位如何被塑造。总之,这种从机制到临床的综合为生物标志物验证、LNM特异性终点和合理治疗干预提供了基于亚型的路线图。
Approximately 20% of cholangiocarcinomas harbor KRAS mutations, with codon 12 variants accounting for most of the cases. Among these, G12V is associated with a poor prognosis, whereas G12D is the most frequent subtype. RMC-6236, a novel RAS (ON) multi-selective inhibitor targeting multiple KRAS codon 12 mutations, has shown promise in early clinical studies in KRAS-mutant cholangiocarcinomas. We evaluated the therapeutic efficacy of the novel RAS (ON) inhibitor RMC-6236 as a monotherapy and in combination with gemcitabine and the anti-EGFR antibody cetuximab in KRAS-mutant cholangiocarcinoma (CCA) models. Antitumor activity and signaling alterations were assessed using in vitro cell-based assays, western blot analysis, and in vivo xenograft models. RMC-6236 potently inhibited cell proliferation in KRAS-mutant (G12D and G12V) cell lines at nanomolar concentrations (10-30 nM) and effectively suppressed pERK signaling. Notably, RMC-6236 treatment was accompanied by increased pEGFR expression, indicating adaptive EGFR feedback activation as a potential mechanism of resistance. In vitro, combination treatments significantly enhanced growth inhibition compared with monotherapy. In xenograft models, RMC-6236 treatment induced dose-dependent tumor regression, whereas combination with cetuximab or gemcitabine further enhanced the antitumor efficacy. EGFR-mediated feedback represents a targetable vulnerability in KRAS-mutant cholangiocarcinomas. Targeting EGFR signaling attenuates adaptive feedback reactivation induced by pan-RAS (ON) inhibition and supports the clinical development of combination strategies with EGFR blockade or cytotoxic chemotherapy.
中文摘要:约20%的胆管癌存在KRAS突变,其中大多数为第12号密码子变异。在这些变异中,G12V与不良预后相关,而G12D是最常见的亚型。RMC-6236是一种新型RAS(ON)多选择性抑制剂,靶向多种KRAS第12号密码子突变,在KRAS突变胆管癌的早期临床研究中显示出前景。我们在KRAS突变胆管癌(CCA)模型中评估了新型RAS(ON)抑制剂RMC-6236单药治疗以及与吉西他滨和抗EGFR抗体西妥昔单抗联合治疗的疗效。通过体外细胞实验、蛋白质印迹分析和体内异种移植模型评估抗肿瘤活性和信号改变。RMC-6236在纳摩尔浓度(10-30 nM)下强效抑制KRAS突变(G12D和G12V)细胞系的细胞增殖,并有效抑制pERK信号。值得注意的是,RMC-6236治疗伴随pEGFR表达增加,表明适应性EGFR反馈激活是潜在的耐药机制。在体外,联合治疗较单药治疗显著增强生长抑制。在异种移植模型中,RMC-6236治疗诱导剂量依赖性肿瘤消退,而与西妥昔单抗或吉西他滨联合进一步增强了抗肿瘤疗效。EGFR介导的反馈代表KRAS突变胆管癌中的一个可靶向弱点。靶向EGFR信号可减弱泛RAS(ON)抑制诱导的适应性反馈再激活,并支持联合EGFR阻断或细胞毒性化疗策略的临床开发。
3胰腺癌/胰十二指肠切除 (3篇)
临床研究 (1篇)
The role of preoperative radiotherapy after neoadjuvant chemotherapy for pancreatic cancer remains controversial. To evaluate whether the addition of radiotherapy to chemotherapy is associated with improved oncologic outcomes in patients undergoing resection for pancreatic cancer. This was a retrospective propensity score-matched cohort study of patients undergoing pancreatic cancer resection between 2015 and 2023, with a median follow-up of 44 months. Patients were recruited from 2 high-volume referral centers. Of patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, those treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin or gemcitabine/nab-paclitaxel with or without preoperative radiation met eligibility criteria. Patients with metastatic disease, surgery-related mortality, or follow-up less than 12 months were excluded. Treatment groups were matched 1:1 on age, sex, comorbidity, tumor characteristics, baseline carbohydrate antigen 19-9 level, resectability status, and chemotherapy exposure. Neoadjuvant chemotherapy with or without radiotherapy. Event-free survival, pattern of recurrence, and overall survival. Of 1201 consecutive patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, 869 met eligibility criteria. Among 800 included patients (median [IQR] age, 65 [58-71] years; 402 men [50.2%]), 438 received neoadjuvant chemotherapy and radiotherapy and 362 chemotherapy alone. After matching, 226 patients per group were analyzed; most had resectable (117 of 226 [51.1%]) or borderline-resectable (104 of 226 [46.5%]) disease. Radiotherapy was associated with higher rates of pathologic complete response (15 of 226 [6.6%] vs 10 of 226 [4.4%]), node-negative disease (139 of 226 [61.5%] vs 76 of 226 [33.6%]), and R0 resection (192 of 226 [85.0%] vs 118 of 226 [52.2%]). Recurrence patterns were similar, with distant recurrence as the predominant first site of failure in both groups (116 of 226 [51.3%] vs 109 of 226 [48.3%]). In competing risk analysis, the cumulative incidence of locoregional recurrence did not differ (subdistribution hazard ratio [HR], 0.90; 95% CI, 0.53-1.54; P = .71). Radiotherapy was not associated with improved event-free survival (HR, 1.10; 95% CI, 0.88-1.37; P = .38) or overall survival (HR, 1.02; 95% CI, 0.79-1.32; P = .84). Results of this cohort study suggest that although the addition of radiotherapy to neoadjuvant chemotherapy was associated with an improved pathologic response, it was not associated with survival benefit or reduced recurrence in resectable and borderline-resectable pancreatic cancer. These findings highlight the limited impact of locoregional control in a disease driven by systemic progression.
中文摘要:新辅助化疗后术前放疗在胰腺癌中的作用仍存在争议。旨在评估在因胰腺癌接受切除术的患者中,在化疗基础上加用放疗是否与肿瘤学结局改善相关。这是一项回顾性倾向评分匹配队列研究,纳入2015年至2023年间接受胰腺癌切除术的患者,中位随访44个月。患者来自2家高容量转诊中心。在接受新辅助治疗并随后行胰腺切除术的胰腺导管腺癌患者中,接受氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂或吉西他滨/白蛋白结合型紫杉醇治疗,伴或不伴术前放疗者符合纳入标准。转移性疾病、手术相关死亡或随访不足12个月的患者被排除。治疗组按年龄、性别、合并症、肿瘤特征、基线碳水化合物抗原19-9水平、可切除状态和化疗暴露进行1:1匹配。暴露为新辅助化疗伴或不伴放疗。结局为无事件生存、复发模式及总生存。在1201例连续接受新辅助治疗后行胰腺切除术的胰腺导管腺癌患者中,869例符合纳入标准。在纳入的800例患者中(中位[IQR]年龄65[58-71]岁;402例男性[50.2%]),438例接受新辅助化疗和放疗,362例仅接受化疗。匹配后,每组分析226例患者;大多数为可切除(117/226[51.1%])或交界可切除(104/226[46.5%])疾病。放疗与更高的病理完全缓解率(15/226[6.6%] vs 10/226[4.4%])、淋巴结阴性率(139/226[61.5%] vs 76/226[33.6%])和R0切除率(192/226[85.0%] vs 118/226[52.2%])相关。复发模式相似,两组均以远处复发为主要首次失败部位(116/226[51.3%] vs 109/226[48.3%])。在竞争风险分析中,局部区域复发的累积发生率无差异(亚分布风险比[HR],0.90;95%CI,0.53-1.54;P=.71)。放疗与无事件生存改善无关(HR,1.10;95%CI,0.88-1.37;P=.38),也与总生存改善无关(HR,1.02;95%CI,0.79-1.32;P=.84)。这项队列研究的结果提示,尽管在新辅助化疗基础上加用放疗与病理缓解改善相关,但在可切除和交界可切除胰腺癌中,其与生存获益或复发减少无关。这些发现凸显了在一种由全身进展驱动的疾病中,局部区域控制的有限影响。
基础研究 (2篇)
Pancreatic intraepithelial neoplasia (PanIN) precedes pancreatic cancer, a deadly disease characterized by an extensive tumor microenvironment. How the microenvironment evolves during cancer progression is largely unknown, as PanINs are microscopic and nondiseased pancreas samples are exceedingly rare, while adjacent normal samples are disrupted by the presence of malignancy. Leveraging donor organs and spatial technologies, we mapped the evolution of PanIN to cancer. The PanIN epithelial component falls on a continuum with cancer, whereas the PanIN microenvironment is drastically distinct. Progression to cancer is accompanied by profound geographic reorganization of myeloid cells and lymphocytes and the formation of a cancer-specific fibroblast population characterized by high levels of smooth muscle actin, LRRC15, and the WNT signaling component LEF1. Together, our data show asynchronous evolution of epithelial and stromal components during pancreatic carcinogenesis. Lack of stromal reprogramming might explain why most PanINs do not progress to cancer. Compiled data available at https://www.pancreas-precancer-atlas.com/. Pancreatic cancer precursor lesions are widely prevalent in the population, but progression to invasive cancer is uncommon. Identifying barriers to cancer progression is critical for cancer interception. Our findings describe unique features of the precancer microenvironment that are likely responsible for keeping precursor lesions from progressing to malignancy.
中文摘要:胰腺上皮内瘤变(PanIN)先于胰腺癌发生,而胰腺癌是一种以广泛肿瘤微环境为特征的致命疾病。微环境在癌症进展过程中如何演变在很大程度上仍不清楚,因为PanIN是微观病变,且无病变胰腺样本极为罕见,而癌旁正常样本又会因恶性肿瘤的存在而受到扰动。利用供体器官和空间技术,我们绘制了PanIN向癌症演变的过程。PanIN的上皮成分与癌症处于同一连续演变谱系,而PanIN微环境则截然不同。向癌症的进展伴随髓系细胞和淋巴细胞深刻的空间格局重塑,以及形成一种癌症特异性成纤维细胞群,该群体以高水平平滑肌肌动蛋白、LRRC15和WNT信号组分LEF1为特征。总之,我们的数据显示,在胰腺癌发生过程中,上皮和间质成分呈异步演变。间质重编程的缺乏可能解释为何大多数PanIN不会进展为癌症。汇总数据可于https://www.pancreas-precancer-atlas.com/获取。胰腺癌前驱病变在人群中广泛流行,但进展为浸润性癌症并不常见。识别癌症进展的障碍对癌症拦截至关重要。我们的研究结果描述了癌前微环境的独特特征,这些特征可能阻止前驱病变进展为恶性肿瘤。
Macroautophagy/autophagy represents a promising therapeutic target in oncology, exhibiting context-dependent roles in tumor progression. Kinase inhibitors are a large group of anti-cancer drugs, and elucidating the regulatory effects of different kinase inhibitors on autophagy offers a valuable strategy to advance our understanding of autophagy regulation in cancer and develop innovative anti-cancer therapies. In this study, we developed a drug screening platform and performed high-content screening using a kinase inhibitor library. The screening identified PTK2/FAK (protein tyrosine kinase 2) inhibitors as potent autophagy inducers. Mechanistic investigations revealed that PTK2/FAK inhibition triggers rapid autophagic flux through a non-classical mechanism dependent on PTK2/FAK expression, which is associated with the spatial redistribution of ER exit sites (ERES). Further analysis demonstrated that PTK2/FAK inhibitor (FAKi)-induced ERES-associated autophagy is not contingent upon full PREB/SEC12 and SEC16 expression, but is sensitized to TMED9 expression level. Additionally, we identified AKAP13 as a novel FAKi-responsive protein that undergoes dephosphorylation upon FAKi treatment and contributes to TMED9-mediated ERES-associated autophagy. Given that ERES-associated autophagy is initiated through membrane contact between ERES and the ER-Golgi intermediate compartment (ERGIC), we further observed enhanced TMED9-ERGIC interactions following FAKi treatment. Furthermore, functional studies confirmed that FAKi-induced autophagy promotes pancreatic ductal adenocarcinoma (PDAC) cell survival both in vitro and in vivo. Collectively, our work unveils a previously unrecognized mechanism of FAKi-mediated autophagy induction and provides new insights for developing targeted therapies against PDAC.Abbreviations: AKAP13: A-kinase anchoring protein 13; AMPK: AMP-activated protein kinase; BAF: bafilomycin A1; ECM: extracellular matrix; ER: endoplasmic reticulum; ERES: endoplasmic reticulum exit sites; ERGIC: ER-Golgi intermediate compartment; GSK: GSK2256098; MTOR: mechanistic target of rapamycin kinase; PDAC: pancreatic ductal adenocarcinoma; PI3K: phosphoinositide 3-kinase; PI4KB: phosphatidylinositol 4-kinase beta; PTK2/FAK: protein tyrosine kinase 2; TMED9: transmembrane p24 trafficking protein 9; ULK1: unc-51 like autophagy activating kinase 1.
中文摘要:巨自噬/自噬是肿瘤学中一个有前景的治疗靶点,在肿瘤进展中发挥依赖情境的作用。激酶抑制剂是一大类抗癌药物,阐明不同激酶抑制剂对自噬的调控效应,为增进我们对肿瘤中自噬调控的理解并开发创新抗癌疗法提供了有价值的策略。在本研究中,我们构建了药物筛选平台,并使用激酶抑制剂文库进行了高内涵筛选。该筛选将PTK2/FAK(蛋白酪氨酸激酶2)抑制剂鉴定为强效自噬诱导剂。机制研究显示,PTK2/FAK抑制通过一种依赖PTK2/FAK表达的非经典机制触发快速自噬流,该机制与内质网出口位点(ERES)的空间重分布相关。进一步分析表明,PTK2/FAK抑制剂(FAKi)诱导的ERES相关自噬并不取决于完整的PREB/SEC12和SEC16表达,但对TMED9表达水平敏感。此外,我们将AKAP13鉴定为一种新的FAKi响应蛋白,其在FAKi处理后发生去磷酸化,并参与TMED9介导的ERES相关自噬。鉴于ERES相关自噬是通过ERES与内质网-高尔基体中间体(ERGIC)之间的膜接触启动的,我们进一步观察到FAKi处理后TMED9-ERGIC相互作用增强。此外,功能研究证实,FAKi诱导的自噬在体外和体内均促进胰腺导管腺癌(PDAC)细胞存活。总之,我们的工作揭示了一种此前未被认识的FAKi介导自噬诱导机制,并为开发针对PDAC的靶向治疗提供了新见解。缩写:AKAP13:A激酶锚定蛋白13;AMPK:AMP活化蛋白激酶;BAF:巴弗洛霉素A1;ECM:细胞外基质;ER:内质网;ERES:内质网出口位点;ERGIC:内质网-高尔基体中间体;GSK:GSK2256098;MTOR:雷帕霉素机械靶蛋白激酶;PDAC:胰腺导管腺癌;PI3K:磷酸肌醇3-激酶;PI4KB:磷脂酰肌醇4-激酶β;PTK2/FAK:蛋白酪氨酸激酶2;TMED9:跨膜p24转运蛋白9;ULK1:unc-51样自噬激活激酶1。
4肝切除/肝癌手术 (2篇)
临床研究 (2篇)
Background Previous studies on imaging of hepatocellular carcinoma (HCC) have shown inconsistency in the growth of tumor vascularity and gross morphologic features. Contrast-enhanced US (CEUS) is one of the few methods that can depict both features simultaneously, making it valuable for assessing this inconsistency and its potential clinical influence. Purpose To evaluate and establish a new CEUS feature representing inconsistency between vascularity and gross morphologic features (perfusion beyond margin [PBM]) and analyze its underlying biologic mechanisms and prognostic influence. Materials and Methods This multicenter retrospective study included patients with HCC from January 2015 to August 2023. Three radiologists (5-8 years of experience) measured tumor diameter using gray-scale US and CEUS. Mathematic, prognostic, and bioinformatics analyses were used to quantify the PBM diagnostic standard. Prognostic analysis included recurrence-free survival after laparoscopic hepatectomy and local tumor progression-free survival after thermal ablation. Bioinformatics analysis included pathologic and immunohistochemical evaluation and RNA sequencing. Results This study included 1076 patients (mean age ± SD, 60 years ± 10.5; 854 men, 1166 HCCs). PBM was defined as the tumor diameter on arterial phase exceeding that at gray-scale US by 5 mm. PBM was associated with worse recurrence-free survival (hazard ratio [HR], 1.76 [95% CI: 1.05, 2.94]; P = .03); worse local tumor progression-free survival (HR, 2.40 [95% CI: 1.84, 3.13]; P < .001); and higher rates of microvascular invasion (52.2% [12 of 23] vs 25.0% [29 of 116]; P = .02), cytokeratin-7 positivity (26.2% [11 of 42] vs 11.3% [14 of 124]; P = .04), and cytokeratin-19 positivity (26.9% [seven of 26] vs 8.8% [13 of 148]; P = .02) compared with the non-PBM group. PBM occurrence was related to upregulation of genes for angiogenesis (VEGA, PIGF), epithelial-mesenchymal transition (TGFB1, MMP2), and immunosuppressive tumor microenvironment (CD163). PBM was more common in patients with cirrhosis (26.8% [236 of 880]; P = .04; odds ratio, 1.41), recurrent tumors (28.4% [161 of 567]; P = .02; odds ratio, 1.38), and tumors greater than 3 cm (30.8% [92 of 298]; P = .01; odds ratio, 1.46). Conclusion Perfusion beyond margin, a new imaging feature, was identified through contrast-enhanced US in patients with hepatocellular carcinoma; it was associated with greater invasive potential and poorer prognosis. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Shafaat and Reis in this issue.
中文摘要:背景:既往关于肝细胞癌(HCC)影像学的研究显示,肿瘤血管生成与大体形态学特征的增长并不一致。对比增强超声(CEUS)是少数能够同时显示这两种特征的方法之一,因此对于评估这种不一致及其潜在临床影响具有价值。目的:评估并建立一种新的CEUS特征,用以表示血管生成与大体形态学特征之间的不一致(边缘外灌注[PBM]),并分析其潜在生物学机制及对预后的影响。材料与方法:这项多中心回顾性研究纳入2015年1月至2023年8月期间的HCC患者。三名具有5至8年经验的放射科医师使用灰阶超声和CEUS测量肿瘤直径。采用数学、预后和生物信息学分析来量化PBM的诊断标准。预后分析包括腹腔镜肝切除术后无复发生存期和热消融后局部肿瘤无进展生存期。生物信息学分析包括病理学和免疫组织化学评估以及RNA测序。结果:本研究纳入1076例患者(平均年龄±标准差,60岁±10.5;854例男性,1166个HCC)。PBM定义为动脉期肿瘤直径超过灰阶超声所测直径5 mm。与非PBM组相比,PBM与更差的无复发生存期相关(风险比[HR],1.76[95%CI:1.05,2.94];P=.03);与更差的局部肿瘤无进展生存期相关(HR,2.40[95%CI:1.84,3.13];P<.001);并与更高的微血管侵犯率(52.2%[12/23] vs 25.0%[29/116];P=.02)、细胞角蛋白7阳性率(26.2%[11/42] vs 11.3%[14/124];P=.04)和细胞角蛋白19阳性率(26.9%[7/26] vs 8.8%[13/148];P=.02)相关。PBM的发生与血管生成基因(VEGA、PIGF)、上皮-间质转化(TGFB1、MMP2)和免疫抑制性肿瘤微环境(CD163)相关基因上调有关。PBM在肝硬化患者中更常见(26.8%[236/880];P=.04;比值比,1.41)、在复发性肿瘤中更常见(28.4%[161/567];P=.02;比值比,1.38),以及在大于3 cm的肿瘤中更常见(30.8%[92/298];P=.01;比值比,1.46)。结论:边缘外灌注是一种通过对比增强超声在肝细胞癌患者中识别出的新影像学特征;它与更强的侵袭潜力和更差的预后相关。© RSNA,2026。本文补充材料可获取。另见本期Shafaat和Reis的社论。
Surgical resection is a cornerstone of curative therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), the two most common primary liver malignancies. In most patients with HCC, underlying cirrhosis is present, whereas in iCCA an identifiable risk factor is often absent. Regardless of tumour type, surgical planning must account for the future liver remnant to minimise the risk of post-hepatectomy liver failure, evaluating not only its volume but also its functional reserve. Furthermore, a deeper knowledge of surgical oncological principles combined with integrative strategies, including systemic and locoregional therapies, has enabled downstaging and conversion of initially unresectable liver malignancies, expanding surgical eligibility across a growing spectrum of hepatic tumoural conditions. Additionally, advances in the understanding of molecular biology and new treatment strategies, particularly in iCCA, have the potential to further extend the boundaries of resectability.
中文摘要:手术切除是肝细胞癌(HCC)和肝内胆管癌(iCCA)这两种最常见原发性肝脏恶性肿瘤根治性治疗的基石。在大多数HCC患者中,存在潜在的肝硬化,而iCCA患者常无可识别的危险因素。无论肿瘤类型如何,手术规划都必须考虑未来残肝,以尽量降低肝切除术后肝衰竭风险,不仅要评估其体积,还要评估其功能储备。此外,对肿瘤外科原则更深入的认识,结合包括系统治疗和局部区域治疗在内的整合策略,已使初始不可切除的肝脏恶性肿瘤得以降期和转化,从而在日益扩大的肝脏肿瘤疾病谱中扩大了手术适应证。另外,对分子生物学的理解进展以及新的治疗策略,尤其是在iCCA中,有可能进一步拓展可切除性的边界。
5肝癌 (2篇)
临床研究 (2篇)
Primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma, represent a growing global health burden marked by rising incidence and high mortality. Clinical management requires integration of tumour stage, liver function, and patient-related factors to guide treatment decisions, yet current frameworks capture only a fraction of underlying disease complexity. In this setting, artificial intelligence (AI) is emerging as a key enabler of precision medicine in liver oncology. AI encompasses machine learning and deep learning approaches capable of identifying complex, non-linear patterns within large, high-dimensional datasets. These methods are increasingly applied across multimodal data inputs, including electronic health records, radiologic imaging, digital pathology, and omics profiling. In imaging, AI supports surveillance, lesion detection, characterisation, and prediction of recurrence, survival, and treatment response. In computational pathology, models are extending tissue analysis beyond description of morphology and marker expression toward prognostic modelling and inference of tumour biology. Integration of clinical, imaging, and pathological data in multimodal AI frameworks has shown superior performance compared with single-modality models for key outcomes such as recurrence and survival. Despite promising results, clinical translation remains limited by insufficient external and prospective validation, limited interpretability of complex models, and regulatory and workflow integration challenges. Addressing these barriers through federated learning strategies and the development of transparent, explainable systems is essential. If successfully implemented, AI-driven multimodal decision-support systems could substantially refine diagnosis, prognostication, and treatment selection in liver cancer, advancing personalised care in this biologically and clinically complex disease.
中文摘要:原发性肝癌,包括肝细胞癌和胆管癌,构成了日益加重的全球健康负担,其发病率上升且死亡率高。临床管理需要整合肿瘤分期、肝功能及患者相关因素以指导治疗决策,但现有框架仅能捕捉疾病内在复杂性的一小部分。在此背景下,人工智能(AI)正成为肝脏肿瘤学精准医疗的关键推动因素。AI涵盖机器学习和深度学习方法,能够识别大型高维数据集中的复杂非线性模式。这些方法越来越多地应用于多模态数据输入,包括电子健康记录、影像学、数字病理学和组学分析。在影像学中,AI支持监测、病灶检测、特征描述以及复发、生存和治疗反应的预测。在计算病理学中,模型正在将组织分析从形态学和标志物表达的描述扩展到预后建模和肿瘤生物学推断。在多模态AI框架中整合临床、影像和病理数据,针对复发和生存等关键结局,已显示出优于单模态模型的性能。尽管结果令人鼓舞,临床转化仍受限于外部验证和前瞻性验证不足、复杂模型可解释性有限,以及监管和工作流程整合方面的挑战。通过联邦学习策略以及开发透明、可解释系统来应对这些障碍至关重要。若成功实施,AI驱动的多模态决策支持系统可显著改善肝癌的诊断、预后判断和治疗选择,推动这一在生物学和临床上均复杂疾病的个性化诊疗。
During the 21st century, the global burden of primary liver cancer has continued to rise, with the absolute numbers of incident cases and deaths increasing by 59.4% and 55.8%, respectively, between 2000 and 2023. Analysis of the GBD 2023 database shows that although age-standardised incidence and mortality rates declined from 2000, this favourable trend reversed around 2020, highlighting the need for continued surveillance. Viral hepatitis remains the leading cause of primary liver cancer worldwide, but its proportional contribution is decreasing. Notably, despite earlier gains from vaccination and antiviral therapies, hepatitis B- and hepatitis C-associated liver cancer incidence and mortality have rebounded globally since 2020. In contrast, metabolic dysfunction-associated steatotic liver disease has exhibited the fastest growth, with sustained increases in age-adjusted incidence and mortality across regions. Marked geographical variation persists in underlying aetiologies, with hepatitis B predominant in East Asia and Sub-Saharan Africa, hepatitis C in the Middle East, North Africa, the Americas, and alcohol-related disease in Europe and Australasia. Additionally, rising incidence and mortality of intrahepatic cholangiocarcinoma underscore the need for dedicated research beyond hepatocellular carcinoma. Collectively, these findings emphasise the urgency of sustained public health and clinical interventions targeting preventable and treatable liver diseases to curb future liver cancer burden.
中文摘要:在21世纪,原发性肝癌的全球负担持续上升,2000年至2023年间,新发病例和死亡的绝对数量分别增加了59.4%和55.8%。对GBD 2023数据库的分析显示,尽管年龄标化发病率和死亡率自2000年起下降,但这一有利趋势在2020年前后发生逆转,凸显持续监测的必要性。病毒性肝炎仍是全球原发性肝癌的主要病因,但其构成比例正在下降。值得注意的是,尽管疫苗接种和抗病毒治疗早期带来了获益,自2020年以来,乙型肝炎和丙型肝炎相关肝癌的发病率和死亡率在全球范围内出现回升。相比之下,代谢功能障碍相关脂肪性肝病增长最快,各地区的年龄调整发病率和死亡率持续上升。潜在病因仍存在明显地理差异:乙型肝炎在东亚和撒哈拉以南非洲占主导,丙型肝炎在中东、北非、美洲占主导,而酒精相关疾病在欧洲和澳大拉西亚占主导。此外,肝内胆管癌发病率和死亡率的上升,凸显了在肝细胞癌之外开展专门研究的必要性。总体而言,这些发现强调了针对可预防和可治疗肝病持续开展公共卫生和临床干预的紧迫性,以遏制未来的肝癌负担。
6肝移植 (1篇)
临床研究 (1篇)
Liver transplantation (LT) remains the most effective curative-intent surgical approach for selected patients with primary hepatic malignancies, owing to its ability to completely replace the diseased liver and address both the tumour and the underlying liver disease. Rather than being determined solely by technical feasibility, transplant candidacy is defined by a dynamic "window of eligibility" based on predicted overall survival and transplant benefit, with repeated assessment of tumour burden, biology, and response to therapy. LT should therefore be viewed as a complex, multi-step process encompassing patient selection, neoadjuvant treatment, graft procurement, surgery, and long-term postoperative management. Neoadjuvant strategies, including bridging, downstaging, and conversion therapies, have become central to patient selection and have expanded transplant eligibility for selected patients with advanced disease through combinations of systemic and locoregional treatments. Following transplantation, minimisation of immunosuppression is essential to balance graft preservation against tumour immune surveillance, although the persistence of antitumour immunity after pre-transplant immunotherapy remains uncertain. Emerging biomarkers, including circulating tumour DNA, circulating tumour cells, and microRNAs, have the potential to improve candidate selection, detect minimal residual disease, and enable earlier, biology-driven identification of recurrence, thereby supporting a more personalised approach to LT in primary liver cancers.
中文摘要:肝移植(LT)仍是经过选择的原发性肝脏恶性肿瘤患者最有效的以治愈为目的的手术方式,因为它能够完全替换病变肝脏,并同时处理肿瘤和基础肝病。移植候选资格并非仅由技术可行性决定,而是由基于预测总生存期和移植获益的动态「合格窗口」来界定,并需反复评估肿瘤负荷、生物学特征和治疗反应。因此,肝移植应被视为一个复杂的多步骤过程,涵盖患者选择、新辅助治疗、移植物获取、手术以及长期术后管理。新辅助策略,包括桥接治疗、降期治疗和转化治疗,已成为患者选择的核心,并通过全身治疗与局部区域治疗的联合,扩大了部分晚期疾病患者的移植资格。移植后,免疫抑制的最小化对于在移植物保护和肿瘤免疫监视之间取得平衡至关重要,尽管移植前免疫治疗后抗肿瘤免疫能否持续仍不确定。新兴生物标志物,包括循环肿瘤DNA、循环肿瘤细胞和microRNA,有潜力改善候选者选择、检测微小残留病,并能够更早地、以生物学驱动的方式识别复发,从而支持原发性肝癌肝移植更加个体化的方法。
7肝癌/胆管癌 (1篇)
临床研究 (1篇)
Liver cancer remains a major global health burden, with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) accounting for the vast majority of primary liver malignancies. As most patients are diagnosed at advanced stages, imaging plays a central role across the entire care continuum - from surveillance and early detection to diagnosis, staging, prognostic stratification, and treatment response assessment. Recent advances in imaging technology, diagnostic frameworks, and computational analysis have substantially expanded the clinical value of liver imaging. This review summarises key developments in liver cancer imaging, beginning with technical innovations in ultrasound, multiphasic and spectral CT, MRI with hepatobiliary contrast agents, abbreviated MRI protocols, and evolving PET tracers such as FAPI. We then examine the convergence and remaining differences among major diagnostic guideline systems for HCC, including LI-RADS, EASL, AASLD, KLCA-NCC, and APASL, with emphasis on vascular hallmarks, hepatobiliary phase interpretation, and Kupffer-phase contrast-enhanced ultrasound criteria. We also discuss the concept of the HCC-iCCA biological continuum, and how imaging features can reflect this phenotypic spectrum. A major focus is the emerging concept of imaging-based prognostication of HCC, which captures biologically meaningful phenotypes such as proliferative class, macrotrabecular-massive subtype, microvascular invasion likelihood, immune microenvironment signatures, and VETC phenotype. We discuss how these imaging features reflect underlying molecular programmes and may inform treatment allocation beyond tumour size and number. In iCCA, advances in quantitative imaging and contrast-enhanced ultrasound perfusion enable differentiation of small-duct vs. large-duct subtypes and prediction of stromal-rich aggressive variants. Treatment response assessment criteria are reviewed, addressing challenges in evaluating locoregional therapies and immunotherapy. Finally, we examine the emerging roles of radiomics and artificial intelligence, focusing on current validation challenges. Together, these advances demonstrate the evolution of liver cancer imaging from a detection tool to a comprehensive platform for biological characterisation and personalised treatment guidance.
中文摘要:肝癌仍是全球主要的健康负担,其中肝细胞癌(HCC)和肝内胆管癌(iCCA)占原发性肝脏恶性肿瘤的绝大多数。由于多数患者确诊时已处于晚期,影像学在整个诊疗连续过程中发挥核心作用——从监测和早期发现,到诊断、分期、预后分层以及治疗反应评估。近年来,影像技术、诊断框架和计算分析的进步显著拓展了肝脏影像学的临床价值。本综述总结肝癌影像学的关键进展,首先介绍超声、多期和能谱CT、使用肝胆对比剂的MRI、简化MRI方案以及诸如FAPI等不断演变的PET示踪剂方面的技术创新。随后,我们审视HCC主要诊断指南体系(包括LI-RADS、EASL、AASLD、KLCA-NCC和APASL)之间的一致性和仍存差异,重点讨论血管性特征、肝胆期判读以及Kupffer期超声造影标准。我们还讨论HCC-iCCA生物学连续体的概念,以及影像特征如何反映这一表型谱。一个主要关注点是基于影像的HCC预后评估这一新兴概念,其可捕捉具有生物学意义的表型,如增殖类、巨梁状-大块型亚型、微血管侵犯可能性、免疫微环境特征和VETC表型。我们讨论这些影像特征如何反映潜在的分子程序,并可能超越肿瘤大小和数目而指导治疗分配。在iCCA中,定量影像和超声造影灌注的进展使得能够区分小胆管型与大胆管型亚型,并预测富含间质的侵袭性变异型。我们回顾治疗反应评估标准,讨论评估局部区域治疗和免疫治疗所面临的挑战。最后,我们探讨影像组学和人工智能的新兴作用,重点关注当前验证方面的挑战。总之,这些进展表明肝癌影像学已从检测工具演变为用于生物学表征和个体化治疗指导的综合平台。
8肺癌 (1篇)
临床研究 (1篇)
The first-in-class pan-RAS inhibitor daraxonrasib shrank tumors in more than 30% of patients with previously treated RAS-mutant non-small cell lung cancer. The findings build on results that recently earned approval for the drug against pancreatic cancer and support an ongoing phase III trial in lung cancer.
中文摘要:首创性泛RAS抑制剂daraxonrasib在既往接受过治疗的RAS突变非小细胞肺癌患者中使超过30%的患者肿瘤缩小。这些发现建立在近期使该药获批用于胰腺癌的结果之上,并支持一项正在进行的肺癌III期试验。
9胰腺炎 (1篇)
基础研究 (1篇)
Pancreatitis is a complex inflammatory condition of the pancreas and can be classified into acute pancreatitis (AP) and chronic pancreatitis (CP). The pathogenesis of the disease remains unclear, and effective preventive or therapeutic strategies are currently lacking. Non-coding RNA (ncRNA) regulatory networks consist primarily of miRNAs, lncRNAs, and circRNAs, which precisely regulate gene expression through complex interactions and play a key role in fibrosis and inflammation. In terms of AP, ncRNAs could modulate the activity of pancreatic acinar cells, autophagic flux, inflammatory cell infiltration and the integrity of the intestinal mucosal barrier, which regulates local pancreatic and systemic inflammation. During the progression of CP, ncRNAs mediate the pancreatic persistent inflammation and collagen deposition by regulating the interactions between pancreatic stellate cells and immune cells. ncRNAs serve as promising non-invasive biomarkers for pancreatitis, enabling early diagnosis, severity stratification, complication prediction and differential diagnosis between CP and pancreatic cancer. Therapeutically, ncRNAs represent potential precision intervention targets due to their high regulatability and specificity, although ncRNA-based therapies currently remain at the preclinical stage. Key challenges such as delivery efficiency and targeting specificity must be addressed to facilitate clinical translation. Overall, ncRNAs offer a novel avenue for improving the clinical management of pancreatitis.
中文摘要:胰腺炎是胰腺的一种复杂炎症性疾病,可分为急性胰腺炎(AP)和慢性胰腺炎(CP)。该病的发病机制仍不明确,目前缺乏有效的预防或治疗策略。非编码RNA(ncRNA)调控网络主要由miRNA、lncRNA和circRNA组成,它们通过复杂的相互作用精确调控基因表达,并在纤维化和炎症中发挥关键作用。就AP而言,ncRNA可调节胰腺腺泡细胞的活性、自噬流、炎症细胞浸润以及肠黏膜屏障的完整性,从而调控胰腺局部和全身炎症。在CP进展过程中,ncRNA通过调节胰腺星状细胞与免疫细胞之间的相互作用,介导胰腺持续性炎症和胶原沉积。ncRNA可作为胰腺炎有前景的无创生物标志物,用于早期诊断、严重程度分层、并发症预测以及CP与胰腺癌的鉴别诊断。在治疗方面,由于ncRNA具有高度可调控性和特异性,其是潜在的精准干预靶点,尽管基于ncRNA的治疗目前仍处于临床前阶段。为促进临床转化,必须解决递送效率和靶向特异性等关键挑战。总体而言,ncRNA为改善胰腺炎的临床管理提供了新途径。
10肝内胆管癌 (1篇)
基础研究 (1篇)
FGFR2 fusion is a common alteration in malignancies, including intrahepatic cholangiocarcinoma (iCCA). While FGFR2 fusion has oncogenic properties, iCCA patients harboring this alteration demonstrate favorable prognosis, remaining a paradox. Here, we delineated the transcriptomic landscape of FGFR2 fusion-positive iCCA. We observed transcriptional features related to PI3K-AKT signaling in tumor cells and reduced neutrophil infiltration, particularly of the PD-L1+ neutrophil subtype. Mechanistically, FGFR2 fusion was associated with reduced H3K27ac enrichment at the CXCL3 promoter and decreased CXCL3 expression in tumor cells, which may contribute to impaired neutrophil recruitment to tumor tissues. In preclinical models, pharmacological FGFR inhibition increased CXCL3 levels and neutrophil infiltration. Combining neutrophil blockade with clinically available FGFR inhibitors enhanced antitumor activity. In conclusion, this study provides mechanistic insights into the paradox between the oncogenic properties of FGFR2 fusion and favorable clinical outcomes in FGFR2 fusion-positive iCCA, and suggests a potential strategy to optimize FGFR2-targeted therapies.
中文摘要:FGFR2融合是包括肝内胆管癌(iCCA)在内的恶性肿瘤中常见的改变。尽管FGFR2融合具有致癌特性,但携带该改变的iCCA患者却表现出较好的预后,这一现象仍是一个悖论。在此,我们描绘了FGFR2融合阳性iCCA的转录组学图谱。我们观察到肿瘤细胞中与PI3K-AKT信号通路相关的转录特征以及中性粒细胞浸润减少,尤其是PD-L1+中性粒细胞亚型。在机制上,FGFR2融合与CXCL3启动子处H3K27ac富集减少以及肿瘤细胞中CXCL3表达下降相关,这可能导致中性粒细胞向肿瘤组织的募集受损。在临床前模型中,药物性FGFR抑制增加了CXCL3水平和中性粒细胞浸润。将中性粒细胞阻断与临床可用的FGFR抑制剂联合使用可增强抗肿瘤活性。总之,本研究为FGFR2融合阳性iCCA中FGFR2融合的致癌特性与良好临床结局之间的悖论提供了机制见解,并提示了一种优化FGFR2靶向治疗的潜在策略。